Lupin Shares Under Scrutiny Following USFDA EIR for Ankleshwar Facility

Lupin Share Price in Focus Amid Regulatory Developments

The pharmaceutical company, Lupin, will remain in the spotlight on May 29, 2026, following the receipt of the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar manufacturing facility in Gujarat.

The EIR was issued after the successful closure of a product-specific pre-approval inspection conducted by the US FDA at the facility from March 2 to March 7, 2026. The inspection outcome reflects Lupin's continued focus on quality excellence and regulatory compliance, reinforcing its commitment to delivering safe and effective medicines to patients worldwide.

In a separate development, Lupin announced that results from its Phase 1a clinical trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The ASCO 2026 Annual Meeting is scheduled to be held from May 29 to June 2, 2026, in Chicago, Illinois.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Lupin also received China's National Medical Products Administration approval for its Abbreviated New Drug Application for Oseltamivir Phosphate, in partnership with Yabao Pharmaceuticals, earlier this month.

In the previous trading session, the share closed at Rs 2,276.75, up Rs 12.90, or 0.57 percent. The share touched a 52-week high of Rs 2,492.00 and a 52-week low of Rs 1,838.65 on 07 May, 2026 and 06 August, 2025, respectively. Currently, the stock is trading 8.64 percent below its 52-week high and 23.83 percent above its 52-week low.